胸腔积液指标测定的临床意义

发布时间：2018-01-26 22:21

本文关键词： 胸腔积液鉴别诊断分子生物学检测技术生物标记物　出处：《中国实用儿科杂志》2017年03期 　论文类型：期刊论文

【摘要】：胸腔积液是一些疾病进展过程中的并发症,其发病率近年来呈现逐年攀升的趋势。胸腔积液的病因较多,其实验室检查包括常规检查以及细胞、生化、免疫学、微生物学检查。感染是儿童胸腔积液的主要原因,针对感染性胸腔积液的分子生物学检测新技术,如聚合酶链反应技术、核酸扩增技术,及部分新型生物标记物,包括降钙素原、C反应蛋白、穿透素-3、芳香族氨基酸等,用于鉴别类肺炎性胸腔积液、结核性胸腔积液或恶性胸腔积液。通过对胸腔积液的实验室检查指标、分子生物学新技术以及新型生物标记物的临床意义进行比较分析,以期能够早期明确儿童胸腔积液的性质进行病因诊断,从而选择适宜的治疗手段,防止病情恶化并改善预后。
[Abstract]:Pleural effusion is a complication in the progress of some diseases. The incidence of pleural effusion is increasing year by year in recent years. The etiology of pleural effusion is more and more, and its laboratory examination includes routine examination, cell, biochemistry, immunology. Microbiological examination. Infection is the main cause of pleural effusion in children. New molecular biological detection techniques for infectious pleural effusion, such as polymerase chain reaction, nucleic acid amplification technology. And some new biomarkers, including calcitonin proto-C-reactive protein, penicillin -3, aromatic amino acids, are used to differentiate pneumonia-like pleural effusion. The clinical significance of tuberculous pleural effusion or malignant pleural effusion was compared and analyzed by laboratory examination, new molecular biological techniques and new biomarkers. In order to identify the nature of pleural effusion in children early to diagnose the etiology and choose the appropriate treatment to prevent the deterioration of the disease and improve the prognosis.
【作者单位】：中国医科大学附属盛京医院小儿呼吸内科;
【分类号】：R725
【正文快照】： 胸膜腔是位于肺和胸壁之间的潜在腔隙。正常情况下胸膜腔内有一层很薄的液体,在呼吸运动时起润滑作用。任何因素使胸膜腔内液体形成过快或吸收过缓,即产生胸腔积液(pleural effusion)。据估计,全球每100万人中就有3000人罹患胸腔积液[1]。胸腔积液通常是一些疾病进展过程中的

【相似文献】